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nation.10 A rapid reduction of the M component, with
disappearance of the marrow plasma-cell infiltration
has been documented late after allo-SCT, at the time
of chronic graft-versus-host disease (GVHD) onset.7
Design and methods
For patients with MM we have recently designed a
program of reduced-intensity conditioning transplant
from HLA-identical sibling donors. The conditioning
combines fludarabine, thiotepa and melphalan (Figu-
re 1). GVHD prophylaxis is based on methotrexate-
cyclosporine, but the latter is rapidly tapered fol-
lowing transplantation to favor the emergence of an
immune-mediated suppression of tumor. DLI are
employed in those patients who remain GVHD-free
but still harbor detectable tumor following cyclospo-
rine tapering. The study is supported by a molecular
analysis of bone marrow cells to detect IgH gene
mutation as a marker of miminal residual disease.4
Results
Twenty patients have been enrolled so far. We have
data on 18 of them. Their characteristics are reported
in Table 1. Seven were transplanted early in the cour-
se of their disease, while 11 had the allograft as treat-
ment for disease progression or relapse. As transplant,
they received a median of 5.1×106/Kg CD34+ cells
(range 0.2-10.2), and 3.0×108/Kg CD3+ cells (range
0.4- 4.2) from bone marrow or granulocyte colony-
stimulating factor (G-CSF)-primed peripheral blood.
Full engraftment occurred in all, with 14 days to reco-
ver >0.5×109/L granulocytes  (range 10-18) and 12
days to recover  >20×109/L platelets (range 4-22).
Acute GVHD is evaluable in 16. Grade 1 GVHD
developed in 4, grade 2 in 3 (18%). None developed
grade >2 acute GVHD. Of the 11 patients evaluable,
6 (54%) developed chronic GVHD. Clinical results
are summarized in Table 2. Thirteen patients are eva-
luable for transplant response. Three of them were
already in complete remission (CR) at the time of
transplantation. Another 2 achieved CR after the allo-
graft, while 6 reached only a partial remission and 2
were refractory.  Twelve patients are currently in fol-
low-up, since 1 died of disease progression soon after
transplantation. Until now there has been a single
relapse. Four patients remain in CR at a median of 12
months follow-up (range 5-15 months).
In multiple myeloma (MM), high-dose therapy fol-lowed by single or autologous stem cell transplan-tation (auto-SCT) represents the treatment of
choice for patients <60 years of age.1,2 However, auto-
SCT is not able to eradicate the disease. In a retro-
spective study of GITMO the event-free survival after
auto-SCT failed to show a plateau. In practice, all
patients relapsed within 3-5 years and later became
resistant to any available treatment. In the meantime,
molecular biology studies confirm that the myeloma
cell clone seldom disappears after autologous tran-
splantation.3,4 The reason is the persistence of a sizea-
ble number of neoplastic cells both in the patient and
in the graft. 
Allogeneic stem cell transplantation (alloSCT) is
employed much less frequently than autologous tran-
splantation, due in part to the limited availability of
HLA-identical donors and in part to the higher tran-
splant-related mortality (TRM).5 Nonetheless, a
retrospective study within the EBMT6 has documen-
ted a TRM reduction over the last few years, as result
of better selection of patients and improvements in
technologies, as may be the preferential use of che-
motherapy-based conditioning instead of total-body
irradiation and the use of stem cells from the periphe-
ral blood rather from bone marrow.7
The emerging concept is that suppression of the
neoplastic clone may be obtained (in selected disea-
ses) even without a mega-dose of chemo-radiothe-
rapy as administered in the traditional transplanta-
tion regimens. An immunosuppressive protocol, in
combination with the infusion of a large number of
stem cells, will ensure stable engraftment and pro-
mote a graft-versus-tumor effect with little toxicity.8
Such methodology is currently under evaluation in a
variety of hematologic disorders, including MM.9
MM is typically an immune-sensitive disease, as wit-
nessed by the efficacy of donor-lymphocyte infusions
(DLI) following allo-SCT and by the results of vacci-
From the Hematology and BMT, S.Camillo-Forlanini Hospital, Rome
(IM, KPU, AL), Hematology Department, S.Martino Hospital, Genoa
(AB), BMT Center, Pescara (PDB), BMT Unit, “V.Cervello” Hospital,
Palermo (RS), Hematology Clinic, Torrette Hospital, Ancona (AO),
Hematology Service, University of Modena (FN), Transplant Unit,
National Cancer Institute, Milan, Italy (PC).
Correspondence: Dr Ignazio Majolino, Unità Operativa di Ematologia e
Trapianti di Midollo Osseo, Azienda Ospedaliera S.Camillo-Forlanini,
Circonvallazione Gianicolense 87, Rome, Italy. Phone: international
+39.06.58704418. Fax: international +39.06.58704357.
E-mail: imajolino@libero.it
Reduced intensity conditioning with thiotepa, fludarabine and melphalan
for allogeneic transplantation in multiple myeloma
I. MAJOLINO, K. P. URAGO, M. RICCARDI, A. LOCASCIULLI, A. BACIGALUPO, P. DI BARTOLOMEO, R. SCIMÈ, A. OLIVIERI, 
F. NARNI, P.CORRADINI
New Insights in Hematology, Venice, Italy, May 15-18, 2003
Haematologica/journal of hematology vol. 88(suppl. 10):May 2003 97
Conclusions and comments
The preliminary results of the present protocol
show that reduced-intensity conditioning with
fludarabine, thiotepa and melphalan is well tole-
rated even in patients who have a long disease
history or who have had previous autograft(s). In
fact, no patient died of transplant-related com-
plications. For this reason this scheme seems to
be applicable also in elderly patients, or when co-
morbidities would discourage the use of tran-
splantation.
In terms of GVHD, our experience is encoura-
ging. Acute GVHD ≥ grade 2 occurred in less
than 20% of patients and we did not observe gra-
de 3 or 4. Chronic GVHD is expected to occur in
Table 1. Patients’ characteristics.
Patients (No.) 18




Previous autotransplant (No.) 10
Time from diagnosis to allo (months) median 8 (3-66)
Table 2. Clinical results.
No. patients
Evaluable 13
In CR at transplantation 3









Design of the protocol.
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over 50% of cases, but this is not to be envisaged
as a negative factor in a disease that is known to
be sensitive to immune aggression.
Our protocol is able to induce a response in a
sizeable proportion of patients. Eighty percent
showed a response, with over 30% CR. Of the 5
patients in CR after transplantation only one has
relapsed. The follow-up is, however, too short to
draw any conclusions on remission duration.
Data on IgH-gene rearrangement will be availa-
ble in the next months, and will probably shed
more light on the significance of CR after this
treatment program.
In conclusion, the reduced-intensity conditio-
ning transplant presented here is considerably
less toxic than conventional conditioning. The
incidence of acute GVHD is limited, and clinical
results appear to be encouraging, as nearly 30%
of patients achieve a complete remission and the
majority maintain this status, at least in the
short-term. We currently offer this program to
patients with an HLA-identical sibling donor at
the time of induction, after 3-4 courses of VAD.
Funding
The present work is in part supported by the
Associazione Italiana per la Ricerca sul Cancro
(AIRC).
References
1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG,
Rossi JF, et al. A prospective, randomized trial of autol-
ogous bone marrow transplantation and chemotherapy
in multiple myeloma. Intergroupe Français du Myelome.
N Engl J Med 1996;335:91-7.
2. Attal M, Harousseau JL, Facon T. Double autologous
transplantation improves survival of multiple myeloma
patients: final analysis of a prospective randomized
study of the "Inter Groupe Français du Myelome".
Blood 2002; 100 Suppl 1:5a[abstract].
3. Majolino I, Vignetti M, Meloni G, Vegna ML, Scime R,
Tringali S, et al. Autologous transplantation in multiple
myeloma: a GITMO retrospective analysis on 290
patients. Haematologica 1999;84:844-52.
4. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M,
Palumb, et al. Molecular and clinical remissions in mul-
tiple myeloma: the role of autologous and allogeneic
transplantation of hematopoietic cells. J Clin Oncol
1999;17:208-15.
5. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demir-
er T, Gooley, et al. Allogeneic peripheral blood stem cell
transplantation in patients with advanced hematologic
malignancies: a retrospective comparison with marrow
transplantation. Blood 1996;88:2794-800.
6. Gahrton G, Svensson H, Cavo M, Apperely J, Bacigalupo
A, Bjorkstrand B, et al. Progress in allogenic bone mar-
row and peripheral blood stem cell transplantation for
multiple myeloma: a comparison between transplants
performed 1983-93 and 1994-8 at European Group for
Blood and Marrow Transplantation centres. Br J Haema-
tol 2001;113:209-16.
7. Majolino I, Corradini P, Scimè R. High rate of remission
and low rate of disease recurrence in patients with mul-
tiple myeloma allografted with PBSC from their HLA-
identical sibling donors. Bone Marrow Transplant 2003;
in press.
8. Slavin S, Nagler A, Naparstek E. Nonmyeloablative stem
cell transplantation and cell therapy as an alternative to
conventional bone marrow transplantation with lethal
cytoreduction for the treatment of malignant and non-
malignant hematologic diseases. Blood 1998;91:756-
63.
9. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M,
Fassas A, et al. Improved outcome of allogeneic trans-
plantation in high-risk multiple myeloma patients after
nonmyeloablative conditioning. J Clin Oncol 2002;20:
1295-303.
10. Bellucci R, Alyea EP, Weller E, Chillemi A, Hochberg E,
Wu CJ, et al. Immunologic effects of prophylactic donor
lymphocyte infusion after allogeneic marrow trans-
plantation for multiple myeloma. Blood 2002;99:4610-
7.
